CompletedPhase 2

Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients

Canada, Denmark59 participantsStarted 2017-05-30

Plain-language summary

The primary objective of this trial is to investigate the safety and efficacy of BI 655130 in patients with PPP following multiple intravenous administrations compared to placebo.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female patients, 18 to 65 years of age at screening. * Palmoplantar Pustulosis * Further inclusion criteria apply Exclusion Criteria: * Presence or known history of anti- Tumor necrosis factor (TNF)-induced Palmoplantar Pustulosis (PPP)-like disease. * Active or latent tuberculosis * Further exclusion criteria apply

What they're measuring

Percentage of Participants With Palmoplantar (pp) Pustular Psoriasis Area and Severity Index 50 (PASI) (ppPASI50) at Week 16

Timeframe: Week 16

Number of Participants With Drug-related Adverse Events (AEs)

Timeframe: From first drug administration until 16 weeks after the last drug administration, up to 32 weeks.

Trial details

NCT IDNCT03135548

SponsorBoehringer Ingelheim

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2018-07-12

Results submitted2019-11-07

View on ClinicalTrials.gov More Psoriasis trials